PDA Cell and Gene Pharmaceutical Products Conference 2027 [Tokyo]
The PDA Cell and Gene Pharmaceutical Products Conference 2027 brings together experts in cell and gene therapy product development, manufacturing, quality and regulatory science. The official agenda includes process development, robotics and artificial intelligence (AI) in manufacturing, and cell and gene therapy product manufacturing.
Event Details
- Official event name: PDA Cell and Gene Pharmaceutical Products Conference 2027
- Dates: 16–17 February 2027 (Tuesday–Wednesday)
- Venue: Tokyo Portcity Takeshiba, Port Hall
- Address: Office Tower, 1F, Tokyo Portcity Takeshiba, 1-7-1 Kaigan, Minato-ku, Tokyo 105-7501, Japan
- Organizer: Parenteral Drug Association (PDA)
- Official event details: PDA Conference Official Website
Key Program Topics
- Process development for cell and gene therapy products
- Robotics and artificial intelligence in cell and gene therapy manufacturing
- Manufacturing of cell and gene therapy products
- Design, qualification, operation and contamination control of GMP facilities for advanced therapies
- Expert Q&A and panel discussions
These topics are drawn from the official agenda and do not represent a separately announced overall conference theme.
Agenda: Tuesday, 16 February
- 10:00–10:10: Opening Remarks
- 10:10–11:55: Session 1 – Opening Session
- 13:15–14:35: Session 2 – Process Development 1
- 15:10–16:40: Session 3 – Process Development 2
- 17:00–18:30: Social Gathering
Selected sessions and times from the official agenda; breaks and registration times are omitted.
Agenda: Wednesday, 17 February
- 09:00–11:40: Session 4 – Robotics & Artificial Intelligence in Cell and Gene Therapy Manufacturing (includes a break)
- 12:40–16:00: Session 5 – Manufacturing of Cell and Gene Therapy Products (includes breaks)
- 16:10–16:45: Fireside Chat
- 16:45–17:00: Summary & Closing Remarks
The agenda is subject to change. Refer to the official PDA agenda for updates.
Selected Presenters
- Christina Meissner, PhD: AGES – Austrian Agency for Health and Food Safety GmbH
- Yoshiaki Maruyama, PhD: Pharmaceuticals and Medical Devices Agency (PMDA)
- Rebecca Jordan: Bristol Myers Squibb
- Wei-Kuang Chi, PhD: Taiwan Bio-Manufacturing Corporation (TBMC)
- Masahiro Kino-oka, PhD: The University of Osaka
- Yoji Sato, PhD: National Institute of Health Sciences
Selected from the presenter list on the official PDA event page; affiliations are those shown by PDA.
Registration & Fees
- Registration: Apply through the official PDA registration page
- Early registration rate deadline: 16 January 2027 (Saturday)
- Standard rates (registrations after 16 January): PDA Member USD 499 / Non-Member USD 699
- Eligible government, health authority and academic PDA members: USD 199 (standard rate; eligibility restrictions apply)
- Currency options: USD and JPY ticket categories are available in the official registration interface
Early-bird prices and JPY amounts are not displayed in the confirmed official information and are therefore omitted. Verify the current rate, eligibility and final payable amount before registering.
Sponsorship & Exhibition
PDA is accepting inquiries from prospective sponsors and exhibitors. The official event page states that the sponsor list is being finalized. Please see the official conference page for further information.
Venue Access
- JR Yamanote / Keihin-Tohoku Lines and Tokyo Monorail: About a 4-minute walk from Hamamatsucho Station
- Yurikamome Line: About a 2-minute walk from Takeshiba Station
- Toei Asakusa / Oedo Subway Lines: About a 5-minute walk from Daimon Station
- Venue floor: Port Hall, 1st Floor, Tokyo Portcity Takeshiba Office Tower
- Official directions: Port Hall access map (English PDF)
Overview
This conference addresses scientific, technical and regulatory considerations in the development, manufacturing and quality of cell and gene therapy products. The official program covers process development, advanced therapy GMP facilities, manufacturing technologies, robotics and AI, and expert discussions.
